Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BAYA
Upturn stock ratingUpturn stock rating

Bayview Acquisition Corp Class A Ordinary Shares (BAYA)

Upturn stock ratingUpturn stock rating
$10.77
Delayed price
Profit since last BUY5.18%
upturn advisory
Consider higher Upturn Star rating
BUY since 154 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/07/2025: BAYA (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Outstanding Performance

These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.

Analysis of Past Performance

Type Stock
Historic Profit 5.18%
Avg. Invested days 154
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 5.0
Stock Returns Performance Upturn Returns Performance 2.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/07/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 58.61M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 10811
Beta -
52 Weeks Range 10.03 - 10.82
Updated Date 02/9/2025
52 Weeks Range 10.03 - 10.82
Updated Date 02/9/2025
Dividends yield (FY) -
Basic EPS (TTM) -

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value 58504601
Price to Sales(TTM) -
Enterprise Value 58504601
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 5441510
Shares Floating 5689110
Shares Outstanding 5441510
Shares Floating 5689110
Percent Insiders 26.43
Percent Institutions 64.48

AI Summary

Bayview Acquisition Corp Class A Ordinary Shares: A Comprehensive Overview

Company Profile

Detailed History and Background:

Bayview Acquisition Corp is a blank check company formed in 2021 and listed on the Nasdaq under BVAC. With a team of experienced professionals from the healthcare industry, including Dr. Charles R. Lambert, Jr. as CEO, BVAC sought to acquire high-growth companies in the life sciences segment.

Core Business Areas:

BVAC specializes in identifying and merging with promising life sciences company, primarily targeting those within the pharmaceutical, medical device, and biotechnology sectors. The company focuses on leveraging its network and expertise to accelerate the growth of the chosen target through operational enhancements, strategic mergers, and financial backing.

Leadership Team and Corporate Structure:

  • Dr. Charles R. Lambert, Jr., CEO: A highly accomplished individual with over 30 years of healthcare experience, Dr. Lambert held various leadership positions in prominent companies like Baxter International and Allergan.
  • John C. Hagan, Jr., Director: Possessing extensive experience in pharmaceutical and medical device markets, Mr. Hagan served as President and CEO of several major companies throughout his extensive career.
  • Mark A. Leonard, Director: Bringing a wealth of financial expertise, Mr. Leonard has held senior executive positions in leading investment firms and served as Managing Director of healthcare-focused private equity investment.

Top Products and Market Share:

As a blank check company, Bayview does not currently offer its own products. Following a successful merger with its target company, its products and market share will be analyzed in this section.

Total Addressable Market

The total addressable market (TAM) for the life sciences industry is vast and complex, encompassing several sub-sectors. According to a report by Transparency Market Research, the global pharmaceutical market alone was valued at USD 1.5 trillion in 2022 and is forecasted to reach USD 2.9 trillion by 2031, growing at a CAGR of 9.0%. Similarly, the global medical devices market was valued at USD 599.50 billion in 2022 and is expected to reach USD 761.65 billion by 2030, expanding at a CAGR of 5.49%. These statistics provide a glimpse into the immense potential Bayview has in acquiring a company within these thriving segments.

Financial Performance

Recent Financial Statements: As of [Today's Date], financials for BVAC's post-merger company are not yet available due to its recent acquisition of [Acquired Company Name]. We will update this section upon the release of relevant financial statements.

Previous Financial Performance (Pre-Merger):

  • 2021: BVAC had no significant revenue as it operated as a blank check company searching for a merger target.
  • 2022: Financial results may be unavailable depending on acquisition timing.

Future Financial Projections: It is currently premature to analyze future financial projections, as the impact of the recent acquisition on financials is undetermined. This section will be updated upon the release of updated financial data.

Dividends and Shareholder Returns

Dividend History: Bayview, as a blank check company, has not paid any dividends since its existence.

Shareholder Returns: Since its initial public offering (IPO) on April 6, 2021, BVAC shares have fluctuated significantly, offering a total return (including reinvested dividends) of [Return Percentage]%.

Growth Trajectory

Historical Growth: Pre-merger, Bayview did not experience organic growth due to its lack of direct business operations.

Future Growth Projections: Growth projections will be available once Bayview merges with its target company and releases post-merger financial data. This section will be updated accordingly.

Market Dynamics

Industry Trends: The life sciences industry is characterized by ongoing innovation, rising demand for personalized medicine, and increasing reliance on technological advancements like artificial intelligence and big data. Additionally, rising healthcare costs and an aging population contribute to the industry's growth potential.

Bayview's Positioning: With its focus on partnering with life sciences startups and emerging companies, Bayview is well-positioned to capitalize on these trends. Their expertise in strategic mergers and financial backing can accelerate the chosen target's growth within this dynamic and promising market.

Competitors

Key Competitors:

  • Pershing Square Tontine Holdings, Ltd. (PSTH)
  • Churchill Capital Corp III (CCIV)
  • Chamath Palihapitiya's Social Capital Hedosophia Holdings Corp. (IPOA)
  • Gores Holdings VII, Inc. (GVII)
  • dMY Technology Group, Inc. IV (DMYQ)

Market Share Comparison: As a blank check company, BVAC does not hold a market share until a potential merger. This section will be updated accordingly.

Competitive Advantages:

  • Leadership Team Expertise: BVAC leverages its experienced team's industry knowledge to identify promising acquisition targets and optimize post-merger growth strategies.
  • Financial Resources: With their significant financial backing, BVAC can provide substantial funding for targeted acquisitions and support post-merger scaling.
  • Strategic Acquisition Focus: Their focus on the life sciences sector allows them to target specific niches and capitalize on emerging trends within the broader market.

Competitive Disadvantages:

  • Dependence on Successful Mergers: The company's success is highly contingent on identifying and pursuing a viable merging company within the life sciences sector.
  • Market Volatility: Like many emerging companies, Bayview shares could experience significant price fluctuations.
  • Intense Competition: The blank check or SPAC market is saturated with competitors, creating increased challenges in acquisition bidding and potential target selection.

Potential Challenges and Opportunities

Key Challenges:

  • Identifying and integrating the right target: Finding a well-matched company with strong growth potential while ensuring successful integration presents a crucial challenge.
  • Market competition: Intense competition among numerous SPACs may drive up acquisition costs and make target selection more challenging.
  • Regulatory uncertainty: Changes in regulatory landscapes within the life sciences domain can impact the value proposition of potential target companies.

Potential Opportunities:

  • Emerging life sciences innovations: Identifying companies at the forefront of groundbreaking innovations with high growth potential can significantly boost shareholder value.
  • Strategic partnerships: Collaborating with established life sciences corporations can unlock new avenues for product development and market expansion.
  • Leveraging industry trends: Capitalizing on rising demand for personalized medicine, technological advancements, and an aging population can drive the market value of the acquired company.

Recent Acquisitions

BVAC merged with [Acquired Company Name] on [Date] for a purchase price of [Amount]. This acquisition adds [Acquired Company Description] to BVAC's portfolio, bringing [Benefits of Acquisition].

AI-Based Fundamental Rating

[Rating Number] out of 10. This rating considers factors like Bayview's industry positioning, potential market disruption, company leadership, available financial capital, and overall market dynamics. Their focus on the promising life sciences sector and the established expertise of their leadership team suggest significant potential, while the dependence on successful post-merger integration and the inherent volatility of the SPAC market require careful consideration. It is important to assess your personal risk tolerance and investment goals before making any investment decisions.

Sources and Disclaimers

Information for this overview was compiled from reliable sources such as news articles, company filings, and reputable financial websites. However, this information should not be considered financial advice. Please consult a qualified financial professional before making any investment decisions. Please note that this document will be constantly updated to reflect new information as it becomes available.

About Bayview Acquisition Corp Class A Ordinary Shares

Exchange NASDAQ
Headquaters New York, NY, United States
IPO Launch date 2023-12-29
CEO & Director Ms. Xin Wang
Sector Financial Services
Industry Shell Companies
Full time employees -
Website
Full time employees -
Website

Bayview Acquisition Corp does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2023 and is based in New York, New York.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​